Evaluate Vantage has been reporting from the Asco 2022 meeting and has covered the following stories so far:
June 5:
Enhertu asks, how low can you go?
Investors clutch at the Tigit straws
June 4:
Merck’s follow-on immuno-oncology plan hits a myositis problem
Abbvie goes back to basics with navitoclax
The Tropical wind blows cold for Trodelvy
June 3:
Related Topics
Share This Article
